Tuberc Respir Dis.
2017 Jan;80(1):93-94. 10.4046/trd.2017.80.1.93.
Is the Combination of ICS and LABA, a Therapeutic Option for COPD, Fading Away?
- Affiliations
-
- 1Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. ymoh55@amc.seoul.kr
- KMID: 2396347
- DOI: http://doi.org/10.4046/trd.2017.80.1.93
Abstract
- No abstract available.
MeSH Terms
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Update on the Safety of Long-acting Beta2-agonists
- The effect of Combination Therapy of Inhaled Corticosteroids and Long-acting Beta2-agonists on Acute Exacerbation in Moderate to Severe COPD Patients
- Potential Masking of Airway Eosinophilic Inflammation by Combination Therapy in Asthma
- Prescription Patterns and Factors Related to the Number of Medications in Chronic Obstructive Pulmonary Disease in Non-elderly Adults
- When is LABA/LAMA Better than LAMA in GOLD Group B or D Patients for Reducing Acute Exacerbations of COPD?
